N-(n-butylcarbamoyl)-L-phenylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(n-butylcarbamoyl)-L-phenylalanine
• 英文别名: (2S)-2-(butylcarbamoylamino)-3-phenylpropanoic acid
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: QVISBXWXOIVWBT-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(n-butylcarbamoyl)-L-phenylalanine benzyl ester 生成 N-(n-butylcarbamoyl)-L-phenylalanine
  参考文献：
  名称：

  Renin inhibitor peptide compounds, a process for the preparation thereof

  摘要：

  该化合物的结构式为：##STR1##其中R.sup.1为芳基，可选择地取代为卤素和卤代(低)烷基；低烷基或环(低)烷基；R.sup.2为氢或低烷基，或R.sup.1和R.sup.2与连接的氮原子一起形成一个杂环基，可选择地取代为低烷基和酯化羧基；R.sup.3为氢或低烷基，R.sup.4为低烷基，以及其药学上可接受的盐，制备方法和包含该化合物的药物组合物。

  公开号：

  US04963530A1

文献信息

• New peptide compounds, a process for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0283970A2

  公开（公告）日：1988-09-28

  A compound of the formula : wherein R1 is aryl optionally substituted with a substituent selected from the group consisting of halogen and halo(lower)alkyl; lower alkyl or cyclo(lower)alkyl; and R2 is hydrogen or lower alkyl, or R' and R2 are taken together with the attached nitrogen atom to form a heterocylic group optionally substituted with a substituent selected from the group consisting of lower alkyl and esterified carboxy, R3 is hydrogen or lower alkyl, and R4 is lower alkyl, and its pharmaceutically acceptable salt, a process for the preparation thereof and pharmaceutical composition comprising the same

  式中的化合物： 其中 R1 是芳基，可任选被选自由卤素和卤代（低级）烷基组成的取代基取代； 低级烷基或环（低级）烷基；以及 R2 是氢或低级烷基，或 R' 和 R2 与相连的氮原子一起形成杂环基团，该杂环基团可选择被选自低 级烷基和酯化羧基的取代基取代、 R3 是氢或低级烷基，以及 R4 是低级烷基、 及其药学上可接受的盐、其制备方法和包含其的药物组合物
• NAMPT AND ROCK INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP2640698A1

  公开（公告）日：2013-09-25
• US4963530A
  申请人：——

  公开号：US4963530A

  公开（公告）日：1990-10-16
• [EN] NAMPT AND ROCK INHIBITORS<br/>[FR] INHIBITEURS DE NAMPT ET ROCK
  申请人：ABBOTT LAB

  公开号：WO2012067965A1

  公开（公告）日：2012-05-24

  Disclosed are compounds of formula (1c) which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
• Renin inhibitor peptide compounds, a process for the preparation thereof
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04963530A1

  公开（公告）日：1990-10-16

  A compound of the formula: ##STR1## wherein R.sup.1 is aryl optionally substituted with a substituent selected from the group consisting of halogen and halo(lower)alkyl; lower alkyl or cyclo(lower)alkyl; and R.sup.2 is hydrogen or lower alkyl, or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with a substituent selected from the group consisting of lower alkyl and esterified carboxy, R.sup.3 is hydrogen or lower alkyl, and R.sup.4 is lower alkyl, and its pharmaceutically acceptable salt, a process for the preparation thereof and pharmaceutical composition comprising the same.

  该化合物的结构式为：##STR1##其中R.sup.1为芳基，可选择地取代为卤素和卤代(低)烷基；低烷基或环(低)烷基；R.sup.2为氢或低烷基，或R.sup.1和R.sup.2与连接的氮原子一起形成一个杂环基，可选择地取代为低烷基和酯化羧基；R.sup.3为氢或低烷基，R.sup.4为低烷基，以及其药学上可接受的盐，制备方法和包含该化合物的药物组合物。